Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibiotic-resistant bacteria
Biotech
Infex advances lung disease candidate after clearing phase 2a
Infex is pushing ahead with development after posting phase 2a data, advancing efforts to enter a market served by Insmed’s Brinsupri.
Nick Paul Taylor
May 21, 2026 4:29am
GSK drops celiac disease program acquired in Sitari buyout
Feb 1, 2023 6:40am
'Uninterpretable' phase 3 results stymie ContraFect
Dec 20, 2022 1:18pm
ContraFect halts phase 3 after antimicrobial fails futility test
Jul 14, 2022 10:35am
Stopping DNA 'packet' exchange could halt bacterial resistance
Jun 14, 2022 8:30am
Lack of policy, investment stifling antibiotics pipeline
Apr 12, 2022 9:00am
